Report: Target Product Profiles: Physician Insights on Key Attributes - Colorectal Cancer (Stage IV), A therapy that improves median overall survival better than the IFL plus bevacizumab regimen for the first-line treatment of stage IV colorectal cancer TOC

Target Product Profiles: Physician Insights on Key Attributes - Colorectal Cancer (Stage IV), A therapy that improves median overall survival better than the IFL plus bevacizumab regimen for the first-line treatment of stage IV colorectal cancer

Published by

Decision Resources, Inc.

Published

2008/03

Content info

37 Pages

Product code

DR65861

Price

From US $ 5625

PDF by E-Mail

Approx. 1-2 business days

Hard Copy/CD-ROM

Approx. 3-4 business days

If you need expedited delivery, please call us.

Introduction
- Using Target Product Profiles in Your Market Strategy
- Report Contents
- Target Product Profile Methodology
Etiology and Pathophysiology
- Overview
- Anatomy
- Pathophysiology
  - Signs and Symptoms
  - Staging
  - Prognosis
  - Metastasis
  - Patterns of Recurrent Disease
- Etiology
  - Colorectal Tumorigenesis Pathways
  - Genetic Changes
  - Role of Epidermal Growth Factor Receptor
  - Role of Insulin-Like Growth Factor
  - Risk Factors
Target Product Profile Discussion-Stage IV Colorectal Cancer
- Target Product Profile Summary for Stage IV Colorectal Cancer-2011
- Assessing Drug Development Opportunities
- Physician Survey Results
  - Effi cacy
  - Safety and Tolerability
  - Delivery
  - Estimated Patient Share
- Pricing Potential
- Forecasted 2016 Pricing Environment
- Competitors to Watch
- Emerging Product Profile

Target Product Profiles: Physician Insights on Key Attributes - Colorectal Cancer (Stage IV), A therapy that improves median overall survival better than the IFL plus bevacizumab regimen for the first-line treatment of stage IV colorectal cancer

Table of Contents